IMPACT-CMH: Impact of Mitral Valve and Subvalvular Abnormalities in Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten | NCT07716826

NCT07716826

Overview

NCT ID: NCT07716826
Lead Sponsor: French Cardiology SocietyOTHER
Official Title: IMPACT-CMH: Impact of Mitral Valve and Subvalvular Abnormalities in Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten
Brief Summary: The objective of this observational study is to evaluate the association between the presence of mitral valvular and/or subvalvular anatomical abnormalities prior to initiation of mavacamten and the hemodynamic response at 6 months in patients with obstructive HCM treated with mavacamten. The secondary objective is to determine the impact of different types of anatomical abnormalities of the mitral valve and subvalvular structures on the hemodynamic and clinical response to mavacamten.
Conditions: Cardiomyopathy, Hypertrophic Obstructive
Interventions

Ages Eligible for Study: Adult (18-64)Older Adult (65+)
Sexes Eligible for Study: All
Accepts Healthy Volunteers?: No
Eligibility Criteria: Inclusion Criteria:

Inclusion Criteria :

Age ≥18 years

Patients who are informed and consent to participate

CMH with significant obstruction (left intraventricular gradient at rest or during Valsalva maneuver ≥ 50 mmHg) and symptomatic (NYHA class 2 or 3)

Patients who have started treatment with Mavacamten

Exclusion Criteria:

Patients who refuse to participate in this register

Central Contacts: Dr Morgane HERRY, MDContact
impact@sfcardio.fr01 44 90 70 28 ext. +33